Letrozole is an oral aromatase inhibitor that lowers estrogen production by blocking the aromatase enzyme; in ovarian cancer it’s used as hormone therapy for estrogen-driven tumors (most commonly low‑grade serous carcinomas and certain sex‑cord stromal tumors) to slow growth or control recurrence.

Letrozole inhibits aromatase, the enzyme that converts androgens to estrogens in fat and other tissues; by reducing circulating estrogen, it deprives estrogen receptor (ER)–positive tumor cells of the growth signals they need, leading to slowed tumor proliferation or tumor shrinkage.

ER‑positive, low‑grade serous ovarian carcinomas and granulosa cell tumors (sex‑cord stromal tumors) are the most likely to respond, because these subtypes commonly depend on estrogen signaling; response in high‑grade serous carcinomas is much less consistent.

Letrozole is FDA‑approved for hormone receptor–positive breast cancer, not specifically for ovarian cancer; its use in ovarian cancer is off‑label and usually considered when tumors show estrogen receptor positivity or when other treatments are unsuitable.

Good candidates are typically postmenopausal patients with ER‑positive, indolent ovarian tumors (e.g., low‑grade serous or granulosa cell tumors), those seeking less toxic systemic therapy, or patients with recurrent disease where hormone sensitivity is suspected or documented.

Letrozole is taken orally once daily; the standard adult dose for cancer treatment is 2.5 mg per day until progression or unacceptable toxicity, with dose adjustments guided by tolerability and clinician judgment.

Responses can take weeks to months; some patients show biochemical or radiologic improvement within 2–4 months, but longer treatment (6–12 months) may be needed to assess benefit in slow‑growing, hormone‑driven ovarian cancers.

Common side effects include hot flashes, joint and muscle pain (arthralgia/myalgia), fatigue, nausea, hair thinning, and vaginal dryness; bone density loss and increased fracture risk are important long‑term concerns in postmenopausal patients.

Serious risks include osteoporosis and increased fracture risk, severe bone pain, and rarely significant cardiovascular events; long‑term estrogen deprivation can affect bone and lipid metabolism, so monitoring and preventive measures are important.

Letrozole is less effective as monotherapy in premenopausal women because active ovaries produce most estrogen; if considered, it is typically combined with ovarian suppression (GnRH agonist or oophorectomy) to achieve postmenopausal hormone levels.

Effectiveness varies by tumor type and ER status; aromatase inhibitors like letrozole generally offer similar mechanisms of estrogen deprivation compared with other endocrine agents, but direct head‑to‑head data in ovarian cancer are limited—choice often depends on prior therapies, side effect profiles, and menopausal status.

Yes; letrozole can be combined sequentially or concurrently with other therapies (e.g., surgery, radiation, targeted agents, or chemotherapy) depending on clinical context, but combinations should be guided by evidence, safety, and specialist input—some targeted combinations are investigational.

Estrogen receptor (ER) and progesterone receptor (PR) status are determined by immunohistochemistry (IHC) on tumor tissue; a positive ER result supports considering letrozole because ER positivity predicts greater likelihood of response to estrogen‑blocking therapies.

Monitor symptoms, bone mineral density (DEXA scans periodically), lipid profile as clinically indicated, and routine labs; imaging and tumor markers (e.g., CA‑125 if previously elevated) are used to evaluate disease response or progression.

No. Letrozole is teratogenic and contraindicated during pregnancy and breastfeeding; women of childbearing potential should use effective contraception during treatment and discuss fertility preservation before starting therapy.

Baseline and periodic bone density testing, calcium and vitamin D supplementation, weight‑bearing exercise, smoking cessation, and considering bisphosphonates or denosumab if osteopenia/osteoporosis or high fracture risk are present are standard measures to reduce bone loss during aromatase inhibitor therapy.

Letrozole reduces estrogen production (aromatase inhibition) while tamoxifen blocks estrogen receptors (selective estrogen receptor modulator); letrozole tends to be preferred in postmenopausal patients with ER‑positive disease due to more complete estrogen suppression, but choice depends on tumor biology, side effects, and prior treatments.

All three lower estrogen by inhibiting aromatase; letrozole and anastrozole are non‑steroidal reversible inhibitors, while exemestane is a steroidal irreversible inhibitor. Efficacy and side effects are generally similar, so clinician preference, tolerability, and specific patient factors guide selection.

Letrozole is less cytotoxic and usually better tolerated than chemotherapy; it’s often used for indolent, hormone‑sensitive recurrences to control disease with fewer systemic side effects, whereas chemotherapy is typically used for bulky, rapidly progressive, or platinum‑sensitive recurrences.

PARP inhibitors and bevacizumab target DNA repair defects or angiogenesis respectively and have strong evidence in specific ovarian cancer populations; letrozole targets hormonal signaling and is considered for ER‑positive tumors. The therapies are not directly interchangeable and may be used sequentially or in combination in trials depending on tumor features.

Surgery (cytoreduction or debulking) aims to remove visible tumor and can be curative or prolong survival in selected patients; letrozole is systemic medical therapy used when surgery is not feasible, as an adjunct, or for slow‑growing hormone‑sensitive disease—decisions depend on disease distribution, symptoms, and goals of care.

In hormone‑sensitive ovarian tumors, letrozole can delay progression compared with observation in some case series and small studies, improving disease control with a favorable toxicity profile; however, large randomized data are limited and benefit must be weighed against side effects and patient preferences.

For premenopausal patients with hormonally driven, low‑burden disease, combining ovarian suppression (GnRH agonists or oophorectomy) with letrozole can be an effective, less toxic alternative to chemotherapy in selected cases; however, chemotherapy remains standard for high‑grade or aggressive disease. Individualized decision‑making is essential.

Fulvestrant directly degrades the estrogen receptor, while letrozole reduces estrogen production; fulvestrant is used parenterally and has a different side effect profile. Evidence in ovarian cancer is limited for both, but mechanism differences may inform use in specific clinical scenarios or trials.

Letrozole has robust, large‑scale evidence and approvals in ER‑positive breast cancer, with well‑established dosing and outcomes; evidence in ovarian cancer is more limited and often off‑label, relying on smaller studies, retrospective series, and biologic rationale—so oncologists apply breast cancer data cautiously when treating ovarian cases.

High‑grade serous carcinomas are typically less hormone‑driven and tend to respond poorly to letrozole, whereas low‑grade serous tumors are more indolent and more likely to benefit from aromatase inhibition; tumor grade and ER status are key determinants of expected response.

Letrozole is metabolized primarily by CYP450 enzymes (notably CYP3A4 and CYP2A6), so strong CYP inhibitors or inducers can affect its levels; chemotherapy and targeted agents have diverse interaction profiles—clinicians review concomitant medications to avoid adverse interactions and maintain efficacy.

If disease progresses on letrozole, options include changing systemic therapy (chemotherapy, targeted agents, other endocrine agents), clinical trials, surgery if feasible, or palliative care—choices depend on tumor biology, prior treatments, pace of progression, and patient goals.

Patients should ask about ER/PR testing results, expected benefits and timeline, side effects (especially bone health), interactions with other drugs, monitoring plans, fertility implications, and alternative or additional treatment options to make an informed, personalized decision.